Companies: 10,795·Total market cap: $144.5T

Psyence Biomedical Ltd.

Psyence Biomedical Ltd.

PBMNASDAQHealthcare● Active

$3.60

+$0.09(+2.56%)

Market Cap$68468

P/E Ratio—

52W High$468.35938

52W Low$1.92

Avg Volume2.6M

Open$3.53

Beta1.65

股票排行：Biotechnology·Healthcare·查看全部市值排行 →

Psyence Biomedical Ltd.（PBM）股票概览

关键指标与盈利、估值、营收、股息等标签页深链。

FMP · PBM · 截至 Jun 9, 2026

关键指标

EPS (TTM)$1.64Earnings history

PE Ratio (TTM)2.2×PE Ratio deep dive

Revenue (TTM)0.00Full revenue history

Dividend Yield不分红Dividend history

Shares Outstanding568,018Shares outstanding history

Next EarningsTBAEarnings history

探索 Psyence Biomedical Ltd. 数据

分析师预测—

股息不分红

盈利EPS $1.78+122.68%

财务快照

FY 2025Revenue$0.00

202320242025

FY 2025Net Income$1.0M▲ +101.98% YoY

202320242025

FY 2025EPS$1.78▲ +122.68% YoY

202320242025

TTM:Revenue: $0.00Net Income: -$26.3MEPS: $1.64View income statement →

竞争对手与同行

#TickerCompanyPriceChangeMkt Cap

Psyence Biomedical Ltd.

$3.60+2.56%$68,468 #2

$0.20-3.24%$2.2M #3

Dermata Therapeutics, Inc.

$1.21+2.54%$824,684 #4

PMGC Holdings Inc.

$1.59+3.25%$3.1M #5

GT Biopharma, Inc.

$0.43-2.57%$4.5M #6

Indaptus Therapeutics, Inc.

$2.10-42.62%$3.7M

股票表现

1D+2.56%

1W-10.22%

1M-35.60%

3M+43.43%

YTD-23.73%

1Y-88.89%

5Y-99.98%

关于 Psyence Biomedical Ltd.

CEOJody Aufrichtig

IPO DateDec 10, 2021

Employees12

CountryCA

Websitepsyencebiomed.com

Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment di…

Biotechnology HealthcareNASDAQCA

关于股票概览与关键数据

Psyence Biomedical Ltd.（PBM）是 Biotechnology 行业的 Healthcare 类公司，于 Dec 10, 2021 在 NASDAQ 上市。截至最近交易日，PBM 股价为 $3.60，市值约为 $68,468。过去12个月累计回报 -88.89%，年初至今回报 -23.73%。

2025 财年 Psyence Biomedical Ltd. 营收 —。完整财务数据（营收历史、盈利、资产负债表）请使用上方标签页。

常见问题

截至最近一个交易日，Psyence Biomedical Ltd.（PBM）股价为 $3.60，在 NASDAQ 上市，52周区间为 $1.92 – $468.36。

PBM 最新股价PBM quote todaylive ticker 实时行情

数据来源：Financial Modeling Prep最后更新：Jun 9, 2026本内容不构成投资建议